Fig. A. Screening Tumor Suppressor Knockdown Cells for Paclitaxel Sensitivity. The MISSION™ TRC Human Tumor Suppressor Gene Family Set (Product No. SH0531) was used to screen for genes that could enhance cell sensitivity to the widely used cancer therapy drug, Paclitaxel. Lentiviral particles were used to transduce A549 cells in 96-well plates and knockdown the corresponding tumor suppressor gene expression. Cells were split into two samples. One sample set was treated with Paclitaxel and the second set received medium only. Results were normalized to pLKO.1-puro empty vector control virus (Product No. SHC001V). Outliers were observed that either conferred more resistance or sensitivity to Paclitaxel treatment.
Fig B. Knockdown Levels of Tumor Suppressor Clones Identified to Have Increased Cell Death in the Presence of Paclitaxel. Multiple clones for four genes conferred increased cell sensitivity to drug treatment. These genes have the potential to be prognostic markers in chemotherapeutic responses.
Send this page to a colleague.
Contact Us
For questions about the library, pricing and quotes or other concerns, please e-mail us at: RNAi@sial.com.
MISSION is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. Label License.
TrakMates is a registered trademark of Matrix Technologies Corporation.
back to top
back to Application Data
shRNA Homepage
RNAi Homepage
|
